Welcome to our dedicated page for ABPRO HLDGS SEC filings (Ticker: ABPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABPRO HLDGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABPRO HLDGS's regulatory disclosures and financial reporting.
Abpro Holdings, Inc. is an early-stage biotechnology company developing next‑generation multispecific antibody drugs for cancer and eye diseases, built on its DiversImmune and TetraBi platforms. The company completed a reverse recapitalization with SPAC Atlantic Coastal Acquisition Corp. II in November 2024 and effected a 1‑for‑30 reverse stock split effective October 31, 2025.
Abpro’s lead oncology asset ABP‑102, partnered worldwide with Celltrion, received FDA clearance of its IND on January 6, 2026, enabling a Phase 1 trial in HER2‑positive solid tumors. Ophthalmology candidate ABP‑201 is licensed regionally to Abpro Bio, with additional T‑cell engager programs ABP‑110 and ABP‑150 in pre‑clinical development.
The business is highly capital constrained. Management discloses substantial doubt about its ability to continue as a going concern and relies on external financing. A $50 million Standby Equity Purchase Agreement with YA II PN, Ltd. funded approximately $1.0 million in 2025 and $6.7 million of net proceeds in early 2026, but became unavailable after Abpro’s common stock was delisted from Nasdaq on February 23, 2026 and moved to the OTC Pink Limited Market. As of June 30, 2025, non‑affiliate market value was about $9.3 million, and 5,896,048 common shares were outstanding as of March 30, 2026.